Metastatic appendicular soft tissue sarcoma treatment and survival outcomes of 2,553 patients from the SEER database

被引:0
|
作者
Gonzalez, Marcos R. [1 ]
Rizk, Paul [2 ]
Hodo, Thomas W. [3 ]
Bedi, Angad [1 ,4 ]
Karczewski, Daniel [1 ]
Lozano-Calderon, Santiago A. [1 ,5 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, Div Orthopaed Oncol, Boston, MA 02144 USA
[2] Univ Florida, Dept Orthopaed Surg, Gainesville, FL 32608 USA
[3] Tulane Univ, Sch Med, Dept Orthopaed Surg, New Orleans, LA 70112 USA
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Orthopaed Surg, Groningen, Netherlands
[5] Massachusetts Gen Hosp, Dept Orthopaed Surg, Div Orthopaed Oncol, Boston, MA 02144 USA
关键词
Soft tissue sarcoma; metastasis; treatment; survival; RHABDOMYOSARCOMA; SURGERY; BREAST; AGE;
D O I
10.20517/2394-4722.2022.138
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Patients with soft tissue sarcoma (STS) that present with metastasis at diagnosis have a dire prognosis. Within this patient population, we sought to assess: (1) demographic and clinical characteristics, (2) metastatic patterns, (3) treatment strategies, and (4) disease-specific survival (DSS).Materials and Methods: The SEER database was queried to identify patients with histologically confirmed STS of the pelvis or extremity. Univariate and multivariate analysis was performed using the Cox proportional hazards model. Disease-specific survival (DSS) was analyzed using the Kaplan-Meier method.Results: A total of 22,683 patients were retrieved, out of which 2,553 (11.3%) had metastasis at diagnosis. Leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), liposarcoma, synovial sarcoma, spindle cell sarcoma, and alveolar rhabdomyosarcoma (A-RMS) were the six most common STS presenting with metastasis. Among patients with metastasis, 53.7% and 33.2% of patients had primary tumors located in the lower limb and pelvis, respectively. Lung was the most common site of metastasis in all subtypes except A-RMS, in which bone metastases and lymph node (LN) predominated (85.2% and 62.1%, respectively). Chemotherapy and radiotherapy were associated with higher DSS (HR = 0.788 and HR = 0.755, respectively). Five-year DSS was below 20% in all tumor histologies. Two-year DSS for patients with synchronous lung and liver metastases was 28%.Conclusion: Although the lung was the most common site of metastasis, metastatic patterns are highly variable depending on tumor histology. Metastatic A-RMS is most commonly presented with regional LN and bone involvement. Disease-specific survival remained poor for patients with metastatic disease at presentation regardless of (neo)-adjuvant radiotherapy or chemotherapy.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy
    Ray-Coquard, I.
    Rizzo, E.
    Blay, J. Y.
    Casali, P.
    Judson, I.
    Hansen, A. Krarup
    Lindner, L. H.
    dei Tos, A. P.
    Gelderblom, H.
    Marreaud, S.
    Litiere, S.
    Rutkowski, P.
    Hohenberger, P.
    Gronchi, A.
    van der Graaf, W. T.
    GYNECOLOGIC ONCOLOGY, 2016, 142 (01) : 95 - 101
  • [32] Clinical Outcomes After Definitive Treatment of Soft Tissue Sarcoma of the Hand: A Retrospective Cohort Study of 109 Patients
    Chapman, Talia R.
    Lavery, Jessica A.
    Nolan, John E.
    Athanasian, Edward A.
    JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 2024, 49 (09): : 867 - 874
  • [33] Analysis of the impact of radiotherapy and surgical treatment regimens based on the SEER database on the survival outcomes of rectal cancer patients over 70 years
    Wei, Wang
    Tongping, Shen
    Jiaming, Wang
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2024, 21 (03) : 4463 - 4484
  • [34] Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study
    Jonsson, L.
    Justo, N.
    Musayev, A.
    Krishna, A.
    Burke, T.
    Pellissier, J.
    Judson, I.
    Staddon, A.
    Blay, J. Y.
    EUROPEAN JOURNAL OF CANCER CARE, 2016, 25 (03) : 466 - 477
  • [35] Nomogram based on pre-treatment inflammatory biomarkers predicting survival in patients with head and neck soft tissue sarcoma
    Chen, Linyan
    Zeng, Hao
    Du, Ze
    Zhao, Yunuo
    Ma, Xuelei
    CANCER BIOMARKERS, 2020, 29 (01) : 151 - 161
  • [36] A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments
    Wagner, Michael J.
    Amodu, Leo Ismaila
    Duh, Mei Sheng
    Korves, Caroline
    Solleza, Franco
    Manson, Stephanie C.
    Diaz, Jose
    Neary, Maureen P.
    Demetri, George D.
    BMC CANCER, 2015, 15
  • [37] A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments
    Michael J Wagner
    Leo Ismaila Amodu
    Mei Sheng Duh
    Caroline Korves
    Franco Solleza
    Stephanie C Manson
    José Diaz
    Maureen P Neary
    George D Demetri
    BMC Cancer, 15
  • [38] Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis
    Nakano, Kenji
    Motoi, Noriko
    Tomomatsu, Junichi
    Gokita, Tabu
    Ae, Keisuke
    Tanizawa, Taisuke
    Matsumoto, Seiichi
    Takahashi, Shunji
    BMC CANCER, 2016, 16
  • [39] Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis
    Kenji Nakano
    Noriko Motoi
    Junichi Tomomatsu
    Tabu Gokita
    Keisuke Ae
    Taisuke Tanizawa
    Seiichi Matsumoto
    Shunji Takahashi
    BMC Cancer, 16
  • [40] The impact of CT-based adipose tissue distribution and sarcopenia on treatment outcomes in patients with high-risk soft tissue sarcoma
    Luc M. Berclaz
    Dorit Di Gioia
    Michael Völkl
    Vindi Jurinovic
    Alexander Klein
    Hans Roland Dürr
    Thomas Knösel
    Bianca Teodorescu
    Stefan Enßle
    Michaela Rippl
    Michael von Bergwelt-Baildon
    Wolfgang G. Kunz
    Lars H. Lindner
    Anton Burkhard-Meier
    BMC Cancer, 25 (1)